Shifa Biomedical Corporation

Shifa Biomedical Corporation is a Malvern Pennsylvania-based drug discovery company founded in 2006. The company is focused on developing cost-effective drugs for cardiovascular disease treatment. Shifa utilizes various scientific methods such as molecular biology, biochemistry, crystallography, and medicinal, computational, and combinatorial chemistry for drug discovery. Their team is composed of highly-experienced scientists with expertise in early stage drug development. The company addresses the unmet need for more aggressive and selective targeted therapies for cardiovascular diseases. Shifa's focus lies on targeting PCSK9, the critical regulatory protein that controls the degradation of the LDL receptor in the liver, contributing to cholesterol homeostasis. They have identified a first-in-class small molecule lead compound, P-21, which interferes with the function of PCSK9 and significantly lowers LDL-C, offering a potential alternative to current treatment options. Shifa's efforts have attracted Seed Round investment from Xontogeny in May 2021. The company operates within the biotechnology and pharmaceutical industries and is headquartered in the United States. With its innovative approach to cardiovascular drug discovery and promising lead compound, Shifa Biomedical Corporation presents an intriguing opportunity for investment in the biopharmaceutical sector.